NT$ 120.5
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable price performance
Data is available to registered users only
Data is available to registered users only
About
HCmed Innovations Co Ltd. provides platforms for inhalation therapy using mesh technology. Its products include Pulmogine and AdheResp. The firm offers comprehensive aerosol characterization analytical services to support the development and optimization of inhalation products. It also offers analytical support in compliance with Pharmacopoeia guidelines. The company was founded by Jason Cheng, Leon Tsai, Shaogi Huang and Simon Hsieh on October 06, 2014 and is headquartered in Taipei, Taiwan.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Data is available to registered users only